Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
Anaplastic thyroid carcinoma (ATC) is one rare type of thyroid carcinoma without standard systemic treatment for advanced disease. Recent evidence has demonstrated promising efficacy of immune checkpoint inhibitors, particularly those targeting programmed death-1 (PD-1)/programmed death ligand 1 (PD...
Saved in:
Main Authors: | Shanmin Fan, Yang Yuan, Yanfang Su, Die Sang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X241313084 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01) -
Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01) -
Metastatic Papillary Thyroid Carcinoma with Multifocal Synchronous Transformation to Anaplastic Thyroid Carcinoma
by: Mark Benedict, et al.
Published: (2016-01-01) -
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
by: Ernest Choy, et al.
Published: (2023-01-01) -
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
by: Ze-Tao Zhan, et al.
Published: (2022-01-01)